Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update

Immunovant, Inc. (IMVT) is up 30.8% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to a new clinical update showing encouraging Week 16 response rates for IMVT-1402 in a difficult-to-treat rheumatoid arthritis study, alongside a broader business and financial update. Investors may be re-pricing the company’s lead program after the company reiterated focus and timelines around IMVT-1402 across multiple autoimmune indications.

Details:

The company disclosed preliminary Week 16 results from an ongoing difficult-to-treat rheumatoid arthritis trial, with ACR20/50/70 response rates of 72.7%, 54.5%, and 35.8% in the open-label period.

The rheumatoid arthritis study’s initial period enrolled 170 participants on weekly subcutaneous dosing, and the trial continues into a randomized portion designed to test durability of response.

The company said its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus is fully enrolled, with topline data expected in the second half of calendar 2026.

Management also highlighted liquidity, stating cash and cash equivalents of about $902.1 million as of March 31, 2026, intended to provide runway through a potential commercial launch of IMVT-1402 in Graves’ disease.

Sources:

GlobeNewswire, Immunovant Investor Relations, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$IMVT Insider Trading Activity

$IMVT insiders have traded $IMVT stock on the open market 25 times in the past 6 months. Of those trades, 1 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $IMVT stock by insiders over the last 6 months:

SCIENCES LTD. ROIVANT purchased 16,666,666 shares for an estimated $349,999,986
TIAGO GIRAO (Chief Financial Officer) sold 25,760 shares for an estimated $763,011
MELANIE GLORIA (Chief Operating Officer) has made 0 purchases and 6 sales selling 24,586 shares for an estimated $604,988.
ANDREW J. FROMKIN has made 0 purchases and 2 sales selling 22,249 shares for an estimated $517,189.
TUYL CHRISTOPHER VAN (Chief Legal Officer) has made 0 purchases and 4 sales selling 18,855 shares for an estimated $491,028.
JAY S STOUT (Chief Technology Officer) has made 0 purchases and 6 sales selling 16,066 shares for an estimated $416,526.
DOUGLAS J. HUGHES has made 0 purchases and 2 sales selling 15,000 shares for an estimated $348,665.
ERIC VENKER (Chief Executive Officer) has made 0 purchases and 2 sales selling 14,229 shares for an estimated $342,854.
ROBERT GRAHAM SUSMAN sold 2,502 shares for an estimated $67,979

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$IMVT Hedge Fund Activity

We have seen 135 institutional investors add shares of $IMVT stock to their portfolio, and 80 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 4,591,235 shares (-88.9%) from their portfolio in Q4 2025, for an estimated $116,709,193
TCG CROSSOVER MANAGEMENT, LLC added 2,797,055 shares (+168.4%) to their portfolio in Q1 2026, for an estimated $68,933,420
JENNISON ASSOCIATES LLC added 2,496,241 shares (+356.4%) to their portfolio in Q1 2026, for an estimated $61,519,859
ARMISTICE CAPITAL, LLC removed 2,182,239 shares (-38.0%) from their portfolio in Q1 2026, for an estimated $53,781,280
POINT72 ASSET MANAGEMENT, L.P. removed 2,000,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $49,290,000
FARALLON CAPITAL MANAGEMENT LLC added 1,534,000 shares (+12783.3%) to their portfolio in Q1 2026, for an estimated $37,805,430
MORGAN STANLEY removed 969,508 shares (-20.0%) from their portfolio in Q1 2026, for an estimated $23,893,524

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$IMVT Price Targets

Multiple analysts have issued price targets for $IMVT recently. We have seen 5 analysts offer price targets for $IMVT in the last 6 months, with a median target of $35.0.

Here are some recent targets:

Corinne Johnson from Goldman Sachs set a target price of $32.0 on 04/15/2026
Douglas Tsao from HC Wainwright & Co. set a target price of $35.0 on 02/10/2026
Yatin Suneja from Guggenheim set a target price of $44.0 on 02/09/2026
Danielle Brill from Truist Securities set a target price of $22.0 on 01/08/2026
Andy Chen from Wolfe Research set a target price of $50.0 on 01/06/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.